Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

BD Launches Innovative Diabetes Pen Needle

Published: Thursday, March 27, 2014
Last Updated: Thursday, March 27, 2014
Bookmark and Share
BD Micro-Fine Ultra™ with Pentapoint 5-bevel technology helps to enhance patient comfort.

BD (Becton, Dickinson and Company) has announced the launch in the UK and Ireland of BD Micro-Fine Ultra™ with 5-bevel needle technology, clinically demonstrated to improve injection comfort for diabetes patients, and enhancing the injection advantages of the current BD Micro-Fine™+ Pen Needle.

A patient study found the five-bevel pen needles to be less painful, easier to insert and more comfortable, when compared with current three-bevel pen needles. This new Pentapoint™ 5-bevel technology is the next in a series of innovations to come from BD Medical - Diabetes Care, resulting in a BD Premium Pen Needle product line which will be called BD Micro-Fine Ultra™.

Studies suggest that as many as one-fifth to one-third of people with diabetes are hesitant or unwilling to give themselves insulin injections for reasons that include needle anxiety. Also, patients who reported injection-related pain or embarrassment intentionally skipped insulin injections more often.

The BD Micro-Fine Ultra™ Pen Needle with Pentapoint™ technology reduces skin penetration force by 23% on average, and is clinically demonstrated to reduce the pain of injection. This may help people with diabetes adhere to an insulin injection regimen and improve outcomes with greater comfort and ease of use.

The BD Micro-Fine Ultra™ with Pentapoint™ needle tip is specially designed with five-beveled edges to create a flatter, thinner surface to penetrate the skin with significantly greater ease, for a smoother and more comfortable injection experience, compared to previous generation three bevel needles. Pentapoint™ technology is available in 4mm pen needles.

Matthias Borst, VP / GM Europe, BD Medical - Diabetes Care, comments: “BD Diabetes Care has been a leader in diabetes injection devices for almost 90 years, and is committed to helping improve the injection experience for the millions of people living with diabetes, through ongoing patient education, the constant pursuit of innovation and improvement, and the development of high-quality products that make a difference. Building on the introduction of the BD Micro-Fine™+ 4mm Pen Needle in 2010, we are confident that our new Pentapoint™ technology will provide an even more comfortable injection experience, helping to minimize injection resistance, fear and anxiety in people with diabetes, enabling them more easily to adopt and adhere to the therapy regimens recommended to improve their diabetes care.”

The BD Micro-Fine Ultra™ 4mm Pen Needle is proven to be as effective as longer needles for patients of all body types, and provides equivalent glucose control by more effectively delivering the insulin dose to subcutaneous tissue (the layer of fat below the skin), the recommended site for insulin injections, and reducing the risk of injecting into muscle.

Intramuscular injection can accelerate insulin absorption and increase the risk of hypoglycemia (abnormally low blood sugar). Subcutaneous injection allows the insulin to be absorbed at an appropriate rate, resulting in better glycaemic control.

The BD Micro-Fine Ultra™ 4mm Pen Needle with Pentapoint technology has delivered a significant step forward in enhancing patient comfort and injection outcomes.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!